在阿尔茨海默病中,UFMylation通路受损
Tingxiang Yan1, Michael G Heckman2, Emily C Craver2
1Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
bioRxiv : the preprint server for biology
|June 21, 2024
概括
阿尔茨海默病的大脑显示UFM1蛋白水平增加,与病理性tau有关. 准UFSP2可能会减少超UFMylation,但操纵UFM1途径需要对阿尔茨海默病治疗方法进行仔细的风险效益分析.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 的特点是团和粉样斑块.
- 在阿尔茨海默病的发病过程中,UFM1 (乌比奎丁类修饰剂) 的作用还没有得到充分研究.
- 以前的研究表明,UFMylation在实验模型中修改了tau聚合.
研究的目的:
- 研究人类AD大脑中UFM1通路的变化.
- 确定UFM1途径组件与AD神经病理学之间的关联.
- 探索UFM1信号对神经元中细胞应激反应的功能影响.
主要方法:
- 分析了来自AD和对照个体的人前额叶和皮质样本中UFM1通路的蛋白质水平.
- 利用多变量回归和邦费罗尼校正来评估与神经病理和生化标志物的关联.
- 与细胞应激路径的RNAseq数据以及基因编辑神经元中验证的发现相关联的UFM1路径组件.
主要成果:
- 人类AD大脑表现出增加的UFM1蛋白水平,主要是结合的UFM1 (超UFMylation).
- 在阿尔茨海默氏症大脑区域,UFMylation水平与病理性tau有很强的相关性.
- 结合的UFM1水平与UFSP2 (deUFMylation酶) 有负相关性,UFM1/UFSP2的变化扰乱了DNA损伤,并在神经元中展开了蛋白质反应.
结论:
- 在人类AD大脑中,UFM1途径发生显著变化,与病理有关.
- UFM1级联可能会在AD中修改tau病理.
- UFSP2是减少AD超UFMylation的潜在目标,但UFM1通路操纵需要进一步评估治疗策略的风险和益处.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在UFM1中,UFM1是UFM1的.在UFMylation中进行化.在UFSP2中,UFSP2是UFSP2.大脑大脑大脑的大脑大脑知道的 知道的 知道的更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
458
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K